Skip to main content

Table 2 Approved indications for kinase-targeted therapies

From: Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia

Disease Kinase target Approved inhibitors
Chronic myeloid leukemia (CML) BCR-ABL1 Imatinib, dasatinib, nilotinib, bosutinib, ponatinib
Ph acute lymphocytic leukemia (ALL) BCR-ABL1 Imatinib, dasatinib, nilotinib, bosutinib, ponatinib
Mastocytosis KIT Imatinib
Hypereosinophilic syndrome (HES) FIP1L1-PDGFRα Imatinib
Chronic eosinophilic leukemia (CEL) FIP1L1-PDGFRα Imatinib
PDGFRβ Imatinib
Gastrointestinal stromal tumors (GIST) KIT; PDGFRα Imatinib
Melanoma BRAF Vemurafenib
Non-small cell lung cancer (NSCLC) EGFR1 Gefinitinib, erlotinib
ALK Crizotinib, ceritinib
Chronic lymphocytic leukemia (CLL) BTK Ibrutinib
Mantle cell lymphoma BTK Ibrutinib
  1. BCR, breakpoint cluster region; ABL1, Abelson murine leukemia viral oncogene homolog 1; KIT, c-kit proto-oncogene; FIP1L1, FIP1-like 1; PDGFRa, platelet-derived growth factor receptor alpha; PDGFRb, platelet-derived growth factor receptor beta; BRAF, B-Raf proto-oncogene; EGFR1, epidermal growth factor receptor 1; ALK, anaplastic lymphoma kinase; BTK, Bruton's tyrosine kinase.